Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26228068 | 0.92 | NAMPT (0.34) | RIPK1NAMPTGAAALDH1A1NPSR1 | |
| SCHEMBL22875262 | 0.91 | GAA (0.39) | RIPK1NAMPTGAAALDH1A1NPSR1 | |
| SCHEMBL22114851 | 0.88 | NAMPT (0.43) | NAMPTGAAALDH1A1NPSR1L3MBTL1 | |
| SCHEMBL7886867 | 0.82 | NAMPT (0.40) | NAMPTALDH1A1TLR9TLR8TLR7 | |
| SCHEMBL26227988 | 0.80 | NAMPT (0.36) | NAMPTALDH1A1L3MBTL1TLR9TLR8 | |
| SCHEMBL22875336 | 0.80 | NAMPT (0.36) | NAMPTALDH1A1TLR9TLR8TLR7 | |
| SCHEMBL22875333 | 0.78 | GRM1 (0.36) | NAMPTALDH1A1CCR2SMYD3 | |
| SCHEMBL26227989 | 0.78 | GRM1 (0.36) | NAMPTALDH1A1CCR2SMYD3 | |
| SCHEMBL22875263 | 0.77 | LMNA (0.34) | GAAALDH1A1NPSR1L3MBTL1CCR2 | |
| SCHEMBL26228087 | 0.77 | TLR9 (0.41) | NAMPTALDH1A1L3MBTL1TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | RIPK1 1142/4885NAMPT 4690/4885GAA 1798/4885 |
| US-20210009559-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | CRBN, IKZF1, IKZF3 | RIPK1 879/4885NAMPT 4578/4885GAA 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.